[go: up one dir, main page]

WO2023027540A1 - Composition pour la prévention, l'amélioration ou le traitement de maladies musculaires comprenant du ginsénoside rc - Google Patents

Composition pour la prévention, l'amélioration ou le traitement de maladies musculaires comprenant du ginsénoside rc Download PDF

Info

Publication number
WO2023027540A1
WO2023027540A1 PCT/KR2022/012781 KR2022012781W WO2023027540A1 WO 2023027540 A1 WO2023027540 A1 WO 2023027540A1 KR 2022012781 W KR2022012781 W KR 2022012781W WO 2023027540 A1 WO2023027540 A1 WO 2023027540A1
Authority
WO
WIPO (PCT)
Prior art keywords
muscle
ginsenoside
oxidative stress
pgc1
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2022/012781
Other languages
English (en)
Korean (ko)
Inventor
김애영
김노수
이해승
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Institute of Oriental Medicine KIOM
Original Assignee
Korea Institute of Oriental Medicine KIOM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Institute of Oriental Medicine KIOM filed Critical Korea Institute of Oriental Medicine KIOM
Publication of WO2023027540A1 publication Critical patent/WO2023027540A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/316—Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles

Definitions

  • the present invention relates to a composition for preventing, improving or treating muscle diseases containing ginsenoside Rc.
  • Skeletal muscle occupies about 40-50% of the human body, and is an organ responsible for body movement and posture maintenance and movement of various organs. Skeletal muscle tends to decrease by about 1% every year after the age of 30, and then rapidly decreases after the age of 65. Muscle loss (muscle loss) is closely related to decreased mobility, falls, osteoporosis, reduced quality of life due to fractures, and hospitalization and death. In addition, a decrease in muscle mass and function leads to a decrease in physical activity, which causes a decrease in total energy consumption, resulting in weight gain and obesity, and as a result, various diseases such as decreased lung function, cardiovascular and metabolic diseases, and the like.
  • Such muscle loss can be caused by damage and dysfunction of mitochondria, which are organelles within muscle cells. , Chronic inflammatory response in muscle cells, disuse due to surgery, lack of exercise due to long-term bed life, and hormonal changes due to aging are known to be the main causes of impaired mitochondrial function in muscle.
  • Ginsenoside is a component having a biological activity of ginseng (scientific name: Panax ginseng ). Ginsenosides are known to exhibit various functions such as anticancer, antihypertensive, antidiabetic, antipain, and tonic actions in the nervous system and non-nervous system. Among them, ginsenoside Rc is known to have an excellent sedative effect compared to other ginsenosides, and is known to inhibit metastasis or proliferation of breast cancer in particular.
  • ginsenoside Rc suppresses muscle damage caused by oxidative stress, thereby suppressing muscle loss and maintaining muscle mass and function, thereby preventing muscle diseases caused by cachexia, decreased muscle function, muscle wasting or muscle degeneration.
  • the present invention was completed by confirming that it could be applied for improvement or treatment.
  • One object of the present invention is to provide a pharmaceutical composition for preventing or treating muscle diseases, comprising ginsenoside Rc as an active ingredient.
  • Another object of the present invention is to provide a method for preventing or treating muscle diseases, comprising the step of treating a subject with a composition containing ginsenoside Rc.
  • Another object of the present invention is to provide a food composition for preventing or improving muscle disease or improving muscle function, containing ginsenoside Rc as an active ingredient.
  • ginsenoside Rc inhibits the death of myoblasts under oxidative stress, increases the activity of PGC1- ⁇ , a metabolic regulation and mitochondrial neosynthetic factor, in myoblasts and myotubes, , Inhibiting the decrease of PGC1- ⁇ and muscle-constituting protein MyH in myotube cells, maintaining mitochondrial mass, and inhibiting the increase of muscle degradation-related proteins MuRF and MAFbx, thereby inhibiting muscle damage caused by oxidative stress Upon confirmation, this can be applied to the prevention, improvement, or treatment of muscle diseases, in particular, muscle diseases caused by decreased muscle function, muscle wasting, or muscle degeneration.
  • Figure 1 shows (A) the result of confirming the cell viability of myoblasts under oxidative stress conditions, (B) the result of confirming the cell viability of myotubes under oxidative stress conditions, and (C) the reduction of mitochondria in myotubes under oxidative stress conditions. This is the diagram showing the result.
  • Figure 2 is (A) the result of confirming the PGC1- ⁇ expression of myoblasts under oxidative stress conditions, (B) the result of confirming the PGC1- ⁇ promoter activity of myoblasts under oxidative stress conditions, (C) the result of confirming the expression of myoblasts under oxidative stress conditions It is a diagram showing the result of confirming PGC1- ⁇ expression and (D) the result of confirming PGC1- ⁇ promoter activity of myotube cells under oxidative stress conditions.
  • Figure 3 is (A) the result of confirming the appropriate concentration of ginsenoside Rc (gRc) for myoblasts, (B) the result of confirming the effect of ginsenoside Rc on myoblast apoptosis under oxidative stress conditions, and (C) ) It is a diagram showing the results confirming the effect of ginsenoside Rc on the PGC1- ⁇ activity of myoblasts under oxidative stress conditions.
  • gRc ginsenoside Rc
  • Figure 4 shows (A) the result of confirming the appropriate concentration of ginsenoside Rc for myotube cells, (B) the result of confirming the effect of ginsenoside Rc on the PGC1- ⁇ promoter activity of myotube cells under oxidative stress conditions, and (C) A diagram showing the results of confirming the effect of ginsenoside Rc on the morphology and mitochondrial mass of myotubes under oxidative stress conditions.
  • One aspect of the present invention is to provide a pharmaceutical composition for preventing or treating muscle diseases, comprising ginsenoside Rc as an active ingredient.
  • Ginsenoside is a component having a biological activity of ginseng (scientific name: Panax ginseng ). Ginsenosides are known to exhibit various functions such as anticancer, antihypertensive, antidiabetic, antipain, and tonic actions in the nervous system and non-nervous system.
  • Gasenoside Rc (Ginsenoside Rc, gRc) is a type of ginsenoside, and is known to have superior sedation compared to other ginsenosides, and in particular, to inhibit metastasis or proliferation of breast cancer.
  • the present invention is significant in that it was confirmed for the first time that the ginsenoside Rc can be applied for prevention, improvement, or treatment of muscle diseases by maintaining muscle mass and function by inhibiting muscle damage caused by oxidative stress.
  • Ginsenoside Rc used in the present invention may be extracted from ginseng collected in nature or purchased commercially, but is not limited thereto.
  • muscle disease is a disease in which limb weakness, gait disorder, etc. occur, and depending on the type, it may be accompanied by weakening of facial muscle strength or weakening of heart and respiratory function. Muscular diseases have more diverse causes than other diseases, and it is often difficult to distinguish them from motor neuron diseases and peripheral nerve diseases, which are other diseases that impair motor function.
  • the muscle disease may be caused by gradual or rapid decline in muscle function, muscle wasting, or muscle degeneration.
  • the muscle disease may be any one or more selected from the group consisting of muscular atrophy, sarcopenia, muscular dystrophy, atony, and cachexia, but Any muscle disease resulting from, without limitation, gradual or rapid decline in muscle function, muscle wasting, or muscle degeneration may be included.
  • prevention refers to any activity that suppresses or delays the onset of muscle disease by administration of the composition
  • treatment means that symptoms caused by muscle disease are improved or advantageously changed by administration of the composition. means any action that
  • the pharmaceutical composition of the present invention may further include suitable carriers, excipients or diluents commonly used in the preparation of pharmaceutical compositions.
  • the content of the active ingredient included in the pharmaceutical composition is not particularly limited thereto, but may include 0.0001% to 10% by weight, specifically 0.001% to 1% by weight based on the total weight of the composition.
  • the pharmaceutical composition is any one formulation selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, internal solutions, emulsions, syrups, sterilized aqueous solutions, non-aqueous solvents, emulsions, freeze-dried formulations, and suppositories. It may have, and may be in various oral or parenteral dosage forms. When formulated, it is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations include at least one excipient, for example, starch, calcium carbonate, sucrose or lactose ( lactose) and gelatin. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used.
  • Liquid formulations for oral administration include solutions, emulsions, syrups, etc., which may include various excipients, such as wetting agents, sweeteners, aromatics, and preservatives, in addition to water and liquid paraffin, which are commonly used simple diluents.
  • Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried formulations, and suppositories.
  • Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspending agents.
  • injectable esters such as ethyl oleate
  • witepsol, macrogol, tween 61, cacao butter, laurin paper, glycerogelatin, and the like may be used as a base for the suppository.
  • composition of the present invention can be administered in a pharmaceutically effective amount.
  • the term "pharmaceutically effective amount” means an amount sufficient to treat a disease with a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is dependent on the type and severity of the subject, age, sex, and disease. It may be determined according to factors including type, activity of drug, sensitivity to drug, administration time, route of administration and excretion rate, duration of treatment, drugs used concurrently, and other factors well known in the medical field.
  • the composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents. And it can be single or multiple administrations.
  • the preferred dosage of the composition of the present invention varies depending on the condition and weight of the patient, the severity of the disease, the drug form, the route of administration and the period, but for a desired effect, the composition of the present invention is 0.0001 to 1,000 mg / kg per day, Specifically, it is preferable to administer 0.001 to 500 mg/kg. Administration may be administered once a day, or may be administered in several divided doses.
  • composition can be administered to various mammals such as rats, livestock, and humans by various routes, and the method of administration includes without limitation as long as it is a conventional method in the art, for example, oral, rectal or intravenous, intramuscular, It may be administered by subcutaneous, intrauterine, or intracerebrovascular injection.
  • composition of the present invention can be used in the form of animal medicine as well as medicine applied to humans.
  • animal is a concept including livestock and companion animals.
  • Another aspect of the present invention is to provide a method for preventing or treating muscle diseases, comprising the step of treating a subject with a composition containing ginsenoside Rc.
  • the term "subject" refers to all animals that have or may have a muscle disease, and by administering the pharmaceutical composition of the present invention to a subject suspected of having a muscle disease, the subject can be efficiently treated.
  • the term "administration” means introducing the pharmaceutical composition of the present invention to a subject suspected of muscle disease by any suitable method, and the route of administration is through various oral or parenteral routes as long as it can reach the target tissue. can be administered.
  • composition of the present invention can be administered in a pharmaceutically effective amount, as described above.
  • the pharmaceutical composition of the present invention is not particularly limited as long as it is an individual for the purpose of preventing or treating muscle diseases, and can be applied to any individual.
  • non-human animals such as monkeys, dogs, cats, rabbits, guinea pigs, rats, mice, cows, sheep, pigs, goats, birds, and fish may be used, and the pharmaceutical composition may be used for oral, parenteral, or subcutaneous administration.
  • the preferred dosage of the pharmaceutical composition of the present invention varies depending on the condition and body weight of the subject, the severity of the disease, the drug type, the route of administration and the period, but can be appropriately selected by those skilled in the art.
  • Another aspect of the present invention is to provide a food composition for preventing or improving muscle disease or improving muscle function, comprising ginsenoside Rc as an active ingredient.
  • the term "improvement” refers to all activities that improve or benefit the symptoms of suspected or affected subjects of muscle diseases by using the composition. Alternatively, it may refer to any action that increases muscle function.
  • Food-wise acceptable salts that can be included in the food composition of the present invention are useful acid addition salts formed from food-acceptable free acids or metal salts formed from bases.
  • inorganic acids and organic acids may be used as free acids.
  • Hydrochloric acid, sulfuric acid, hydrobromic acid, sulfurous acid, or phosphoric acid may be used as the inorganic acid
  • citric acid, acetic acid, maleic acid, fumaric acid, gluconic acid, methanesulfonic acid, or the like may be used as the organic acid.
  • an alkali metal salt or an alkaline earth metal salt, sodium, potassium or calcium salt may be used as the metal salt. However, it is not limited thereto.
  • the food composition of the present invention includes forms such as pills, powders, granules, precipitates, tablets, capsules or liquids, and the food to which the composition can be added includes, for example, various foods, such as beverages, There are chewing gum, tea, vitamin complexes, and health supplements.
  • Ingredients that can be included in the food composition of the present invention are not particularly limited to other ingredients other than containing active ingredients as essential ingredients, and, like conventional foods, various herbal extracts, food supplement additives, or natural carbohydrates as additional ingredients. may contain The content of the active ingredient in the food composition may be appropriately determined depending on the purpose of use (prevention, improvement or therapeutic treatment). At this time, the content of the active ingredient included in the composition is not particularly limited thereto, but may include 0.0001% to 10% by weight, specifically 0.001% to 1% by weight based on the total weight of the composition.
  • the food auxiliary additives may include food auxiliary additives common in the art, for example, flavoring agents, flavoring agents, coloring agents, fillers, stabilizers, and the like.
  • natural carbohydrates examples include monosaccharides such as glucose, fructose, and the like; disaccharides such as maltose, sucrose and the like; and polysaccharides such as conventional sugars such as dextrins, cyclodextrins, and the like, and sugar alcohols such as xylitol, sorbitol, and erythritol.
  • natural flavors eg, rebaudioside A, glycyrrhizin, etc.
  • synthetic flavors sacharin, aspartame, etc.
  • the food composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and fillers (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its Salts, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, and the like may be contained.
  • it may contain fruit flesh for the production of natural fruit juice, fruit juice beverages and vegetable beverages. These components may be used independently or in combination.
  • the health supplement may include health functional food and health food.
  • the health functional food is the same term as food for special health use (FoSHU), and has high medical effect and is processed to efficiently display bioregulatory functions in addition to nutrient supply. means food.
  • function (sex) means obtaining useful effects for health purposes such as regulating nutrients for the structure and function of the human body or physiological functions.
  • Food containing the food composition of the present invention can be prepared by a method commonly used in the art, and can be prepared by adding raw materials and components commonly added in the art during the preparation.
  • the formulation of the food may also be prepared without limitation as long as the formulation is recognized as a food.
  • the food composition of the present invention can be prepared in various types of formulations, and unlike general drugs, it has the advantage of not having side effects that may occur when taking drugs for a long time by using food as a raw material, and has excellent portability.
  • Another aspect of the present invention is to provide a use of ginsenoside Rc for preventing, treating or improving muscle diseases.
  • Another aspect of the present invention is to provide a use for improving muscle function of ginsenoside Rc.
  • Example 1 Observation of changes in myoblasts and myotubes under oxidative stress conditions
  • Example 1-1 Quantification of survival rate of myoblasts under oxidative stress conditions
  • Myoblasts were cultured in 10% Fetal Bovine Serum (FBS)/DMEM (GM: growth medium), and H 2 O 2 was added at concentrations of 0, 0.1, 0.25, 0.5, and 1 mM to induce oxidative stress. After treatment, it was cultured for 24 hours.
  • FBS Fetal Bovine Serum
  • DMEM DMEM
  • Example 1-2 Confirmation of morphological changes and survival rate of myotubes under oxidative stress conditions
  • Myotubes were differentiated for a total of 5 days by adding 2% horse serum (HS)/DMEM (differentiation medium) to myoblasts, replacing the medium every 2 days.
  • HS horse serum
  • DMEM differentiation medium
  • H 2 O 2 was treated at concentrations of 0, 0.1, 0.25, 0.5, and 1 mM, and cultured for 24 hours.
  • Example 1-3 Confirmation of mitochondrial mass of myotubes under oxidative stress
  • H 2 O 2 was treated at concentrations of 0, 0.25, and 0.5 mM, and cultured for 24 hours.
  • Myotubes were stained with MitoTracker to quantify mitochondrial mass through image analysis.
  • Example 2 Changes in mitochondrial neosynthetic factor PGC1- ⁇ expression and activity in myoblasts and myotubes under oxidative stress
  • Example 2-2 Confirmation of PGC1- ⁇ promoter activity in myoblasts under oxidative stress conditions
  • Myoblasts were co-transfected with the mPGC1- ⁇ -luciferase/ ⁇ -gal reporter gene, and 6 hours later, H 2 O 2 was added at 0, 0.1, 0.25, or 0.5 mM to induce oxidative stress. After treatment with the concentration, it was cultured for 12 hours.
  • H 2 O 2 was treated at concentrations of 0, 0.25, and 0.5 mM, and cultured for 24 hours.
  • Example 2-4 Confirmation of PGC1- ⁇ promoter activity in myotubes under oxidative stress conditions
  • Myotube cells differentiated for 5 days were co-transfected with the mPGC1- ⁇ -luciferase/ ⁇ -gal reporter gene, and 6 hours later, H 2 O 2 was added at concentrations of 0, 0.1, 0.25, and 0.5 mM to induce oxidative stress. After treatment, it was cultured for 12 hours.
  • gRc PHS89210, Sigma
  • Example 3-2 Confirmation of the effect of gRc on myoblast apoptosis under oxidative stress conditions
  • Myoblasts were pretreated with gRc at concentrations of 5, 10, 25, or 50 ⁇ M for 18 hours, and then treated with 0.25 mM H 2 O 2 to induce oxidative stress, followed by additional culture for 24 hours.
  • the cell viability decreased by about 55% by the H 2 O 2 treatment, and the gRc pretreated group showed a concentration-dependent increase in cell viability compared to the gRc untreated group (FIG. 3B).
  • Example 3-3 Confirmation of the effect of gRc on PGC1- ⁇ promoter activity in myoblasts under oxidative stress conditions
  • Myoblasts were co-transfected with the mPGC1- ⁇ -luciferase/ ⁇ -gal reporter gene, and 6 hours later, gRc was pretreated at concentrations of 10, 25, and 50 ⁇ M for 12 hours. To induce oxidative stress in gRc-pretreated myoblasts, 0.25 mM H 2 O 2 was treated for 12 hours.
  • the PGC1- ⁇ promoter activity was increased in a concentration-dependent manner by treatment with gRc alone, and in particular, the PGC1- ⁇ promoter activity was increased by about 36% at 50 ⁇ M gRc (FIG. 3C).
  • Example 4 Confirmation of the effect of ginsenoside Rc (gRc) on mitochondrial mass and PGC1- ⁇ promoter activity in myotubes under oxidative stress conditions
  • myotubes differentiated for 5 days were treated with gRc at a concentration of 0-100 ⁇ M and cultured for 24 hours.
  • Example 4-2 Confirmation of the effect of gRc on PGC1- ⁇ promoter activity in myotubes under oxidative stress conditions
  • Myotube cells differentiated for 5 days were co-transfected with the mPGC1- ⁇ -luciferase/ ⁇ -gal reporter gene, and 6 hours later, gRc was pretreated at concentrations of 10, 25, and 50 ⁇ M for 12 hours. To induce oxidative stress in myotubes pretreated with gRc, 0.25 mM H 2 O 2 was treated for 12 hours.
  • the PGC1- ⁇ promoter activity was increased in a concentration-dependent manner by treatment with gRc alone, and in particular, the PGC1- ⁇ promoter activity was increased by about 27% at 25 ⁇ M gRc (FIG. 4B).
  • Example 4-3 Confirmation of gRc effect on myotube cell morphology and mitochondrial mass under oxidative stress conditions
  • Myotube cells differentiated for 5 days were pretreated with gRc at concentrations of 10, 25, and 50 ⁇ M for 12 hours, and then treated with 0.25 mM H 2 O 2 for 24 hours to induce oxidative stress.
  • the morphology and mitochondrial mass of myotube cells were confirmed by observation under an inverted microscope (Phase) and MitoTracker staining.
  • Example 5 Confirmation of the effect of ginsenoside Rc (gRc) on the expression of proteins related to myotube cell degradation under oxidative stress conditions
  • Myotube cells differentiated for 5 days were pretreated with gRc at concentrations of 10, 25, and 50 ⁇ M for 12 hours, and then treated with 0.25 mM H 2 O 2 for 24 hours to induce oxidative stress.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pour la prévention, l'amélioration ou le traitement de maladies musculaires, comprenant du ginsénoside Rc. Le ginsénoside Rc inhibe l'apoptose des myoblastes sous stress oxydatif, augmente l'activité de PGC1-α, qui est un régulateur métabolique et un facteur de biogenèse mitochondriale, dans les myoblastes et les myotubes, inhibe la réduction de PGC1-α et de MyH dans les myotubes, maintient la masse mitochondriale, et supprime les dommages musculaires provoqués par le stress oxydatif par inhibition d'une augmentation de MuRF et de MAFbx, qui sont des protéines impliquées dans la dégradation des cellules musculaires, et peuvent donc être utilisées pour la prévention, l'amélioration ou le traitement de maladies musculaires, en particulier des maladies musculaires provoquées par une diminution de la fonction musculaire, une fonte musculaire ou une dégénérescence musculaire.
PCT/KR2022/012781 2021-08-26 2022-08-26 Composition pour la prévention, l'amélioration ou le traitement de maladies musculaires comprenant du ginsénoside rc Ceased WO2023027540A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2021-0113215 2021-08-26
KR1020210113215A KR102702289B1 (ko) 2021-08-26 2021-08-26 진세노사이드 Rc를 포함하는 근육 질환의 예방, 개선 또는 치료용 조성물

Publications (1)

Publication Number Publication Date
WO2023027540A1 true WO2023027540A1 (fr) 2023-03-02

Family

ID=85323352

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2022/012781 Ceased WO2023027540A1 (fr) 2021-08-26 2022-08-26 Composition pour la prévention, l'amélioration ou le traitement de maladies musculaires comprenant du ginsénoside rc

Country Status (2)

Country Link
KR (1) KR102702289B1 (fr)
WO (1) WO2023027540A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102125594A (zh) * 2010-01-12 2011-07-20 河北以岭医药研究院有限公司 一种中药冻干注射剂中活性化合物含量的测定方法
KR101917794B1 (ko) * 2018-05-10 2018-11-13 한국과학기술원 진세노사이드 Rh2를 포함하는 근육 질환 개선, 예방 또는 치료용 조성물
KR20190108777A (ko) * 2018-03-15 2019-09-25 숙명여자대학교산학협력단 진세노사이드 Rb1 및 Rb2를 유효성분으로 함유하는 근육 재생용 조성물
KR20210050475A (ko) * 2019-10-28 2021-05-07 한국식품연구원 진세노사이드 Rf, 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물을 유효성분으로 포함하는 근기능 개선용 조성물
KR20210074901A (ko) * 2019-12-12 2021-06-22 아레즈 주식회사 진세노사이드 Rg2, Rg4, Rg6, Rh1 및 Rh4를 유효성분으로 포함하는 근육 질환 예방 또는 치료용 약학 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102125594A (zh) * 2010-01-12 2011-07-20 河北以岭医药研究院有限公司 一种中药冻干注射剂中活性化合物含量的测定方法
KR20190108777A (ko) * 2018-03-15 2019-09-25 숙명여자대학교산학협력단 진세노사이드 Rb1 및 Rb2를 유효성분으로 함유하는 근육 재생용 조성물
KR101917794B1 (ko) * 2018-05-10 2018-11-13 한국과학기술원 진세노사이드 Rh2를 포함하는 근육 질환 개선, 예방 또는 치료용 조성물
KR20210050475A (ko) * 2019-10-28 2021-05-07 한국식품연구원 진세노사이드 Rf, 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물을 유효성분으로 포함하는 근기능 개선용 조성물
KR20210074901A (ko) * 2019-12-12 2021-06-22 아레즈 주식회사 진세노사이드 Rg2, Rg4, Rg6, Rh1 및 Rh4를 유효성분으로 포함하는 근육 질환 예방 또는 치료용 약학 조성물

Also Published As

Publication number Publication date
KR102702289B1 (ko) 2024-09-04
KR20230030938A (ko) 2023-03-07

Similar Documents

Publication Publication Date Title
WO2017039365A1 (fr) Méthode d'inhibition de l'absorption et/ou de promotion de l'excrétion de lipides à l'aide de d-psicose
WO2021194110A1 (fr) Composition pour prévenir ou traiter des maladies métaboliques, contenant du jujuboside en tant que principe actif
WO2024048934A1 (fr) Nouvelle bactérie lactique lactiplantibacillus plantarum sko-001 pour réduire la graisse corporelle, et ses utilisations
WO2020071660A1 (fr) Composition anti-âge contenant comme principe actif une souche d'akkermansia muciniphila ou une culture de cette dernière
WO2019231220A1 (fr) Utilisation d'un composé thiophène 2,3,5-substitué pour prévenir, atténuer ou traiter des cancers du sein
WO2020040432A1 (fr) Composition pharmaceutique pour prévenir ou traiter des maladies musculaires, contenant un extrait de baie de ginseng en tant que principe actif
WO2018070707A1 (fr) Composition pour la prévention ou le traitement de maladie musculaire, contenant comme principe actif decanal ou un sel pharmaceutiquement acceptable de celui-ci
WO2017082478A1 (fr) Composition pharmaceutique visant à prévenir ou traiter l'ostéoporose et contenant un extrait de germe de soja
WO2022231294A1 (fr) Composition destinée à prévenir, à atténuer ou à traiter la pigmentation de la peau
WO2023027540A1 (fr) Composition pour la prévention, l'amélioration ou le traitement de maladies musculaires comprenant du ginsénoside rc
WO2025150903A1 (fr) Nouveau peptide ayant des activités d'inhibition de la perte musculaire et de promotion de la croissance musculaire et ses utilisations
WO2023017958A1 (fr) Composition pour la prévention, le traitement ou le soulagement de l'arthrite, comprenant un extrait d'elaeocarpus sylvestris ou un mélange d'extrait d'elaeocarpus sylvestris et de sulfasalazine en tant que principe actif
WO2019078381A1 (fr) Composition pharmaceutique, composition alimentaire et additif alimentaire pour prévenir, soulager ou traiter la perte, la faiblesse et l'atrophie musculaires, contenant, à titre de principe actif, une bactérie enterococcus faecalis, le liquide de culture ou des cellules mortes de celle-ci
WO2020204479A1 (fr) Composition pour soulager des troubles de la circulation veineuse comprenant un extrait de feuille de raisin et un extrait de centella asiatica
WO2017082479A1 (fr) Composition pharmaceutique destinée à la prévention ou au traitement de l'obésité comprenant un extrait embryonnaire de fève germée
WO2016133352A1 (fr) Composition visant à prévenir, soulager ou traiter les maladies métaboliques, contenant de l'amodiaquine en tant que principe actif
WO2019209061A1 (fr) Composition favorisant la croissance osseuse comprenant de l'allium fistulosum linn en tant que principe actif
WO2022270760A1 (fr) Méthode de traitement de la stéatohépatite non alcoolique par la co-administration d'un dérivé de la curcumine et d'un inhibiteur du récepteur de tgf-β
WO2022149901A1 (fr) Composition de prévention, de soulagement ou de traitement de maladies musculaires, contenant un extrait de gardenia jasminoides en tant que principe actif
WO2022182199A1 (fr) Composition contenant un extrait à l'eau chaude de cassis pour prévenir, soulager ou traiter les maladies du foie gras non alcooliques
WO2022231309A1 (fr) Composition alimentaire et composition pharmaceutique pour prévenir ou soulager la sarcopénie, contenant du collagène de faible poids moléculaire en tant que principe actif
WO2020040522A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de maladies musculaires comprenant un extrait de codonopsis lanceolata en tant que composant efficace
WO2021033995A1 (fr) Composition comprenant un extrait d'amomum tsaoko pour prévenir, atténuer ou traiter une maladie liée à la sarcopénie
WO2021020841A1 (fr) Composition pour la prévention ou le traitement d'une maladie hépatique métabolique
WO2021201507A1 (fr) Composition pour prévenir, améliorer ou traiter la sarcopénie, comprenant une protéine de larves de tenebrio molitor ou un hydrolysat de celle-ci en tant que principe actif

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22861748

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22861748

Country of ref document: EP

Kind code of ref document: A1